Liptruzet

Atorvastatin Calcium/Ezetimibe, the active ingredients in Liptruzet, are a statin and cholesterol absorption inhibitor combination presented as a tablet for oral use. It treats hyperlipidemia and reduces cardiovascular risk in adult patients. GNH USA supplies Liptruzet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liptruzet is indicated for disorders of lipid metabolism and for cardiovascular risk reduction. Primary hypercholesterolemia: lowers LDL‑C and total cholesterol levels. Mixed dyslipidemia: reduces LDL‑C, triglycerides and raises HDL‑C. Familial hypercholesterolemia: improves lipid profile in genetically high‑cholesterol patients. Prevention of cardiovascular events in high‑risk patients: decreases incidence of myocardial infarction and stroke.

Liptruzet may cause a range of adverse reactions.

Common Side Effects: - Headache - Muscle pain or weakness - Abdominal discomfort - Diarrhea - Nausea - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Rhabdomyolysis or severe myopathy - Acute liver injury or hepatitis - Severe allergic reactions (e.g., anaphylaxis) - Pancreatitis - Marked CK elevation with renal impairment - Fulminant hepatic failure

Before initiating Liptruzet, several safety considerations are recommended. Liver function monitoring: assess baseline and periodic liver enzymes. Muscle toxicity monitoring: watch for unexplained muscle pain, weakness, or dark urine. Drug interaction review: evaluate concomitant medications that affect CYP3A4 or statin metabolism. Pregnancy and lactation: avoid use unless benefits outweigh potential risks and under close supervision. Renal impairment: use caution and consider dose adjustment in severe renal dysfunction. Store at ambient temperature: keep below 25°C, protect from moisture and light, and retain in original packaging.

Liptruzet can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin exposure and risk of muscle toxicity. - Cyclosporine: markedly raises statin levels, heightening myopathy risk. - Gemfibrozil: combined use raises risk of rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum hydroxide): may reduce ezetimibe absorption, monitor lipid response. - St. John’s wort: may lower atorvastatin exposure, consider alternative therapy.